Home
Cabaletta Bio

Cabaletta Bio Market Share Analysis for June 2026

Do you have a question or comment? Contact Cabaletta Bio today to find out more about our cell therapy product candidates for patients with autoimmune diseases.

Health > Biotechnology and Pharmaceuticals

Domaincabalettabio.com

Year Founded2017

Employees51 - 200

Annual Revenue$10M - $15M

Cabaletta Bio

Cabaletta Bio (including company regionals)

cabalettabio.com

See more website traffic and engagement information

Cabaletta Bio Revenue up to June 2026 is 10M - 15M

revenue generated by Cabaletta Bio top domains

Cabaletta Bio top domains revenue over 3 years

Revenue for Cabaletta Bio top domains

cabalettabio.com10M - 15M

See more with Sales Intelligence

Total visits to Cabaletta Bio's top domains

Understand Cabaletta Bio market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

cabalettabio.com17.2K

See more with Sales Intelligence

Avg. visit duration in Cabaletta Bio's top domains

Analyze Cabaletta Bio engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

cabalettabio.com00:01:42

See more with Sales Intelligence

Avg. pageviews on Cabaletta Bio's top domains

See how Cabaletta Bio keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

cabalettabio.com2.42

See more with Sales Intelligence

Cabaletta Bio top competitors by domain

Top similar sites in June 2026, ranked by their affinity

stemcyte.comCompany NameStemCyteEmployees51 - 200HQUnited States, California, Baldwin ParkAnnual revenue$15M - $25MTotal visits4.2KHealth > Health - Other

Top technologies used by Cabaletta Bio

These are the website technologies, by industry, used by Cabaletta Bio top domains

Widget (4)

reCAPTCHA

Advertising (2)

DoubleClick

Audio Video Media (2)

YouTube

Content Management System (2)

WordPress

More Technologies

5

See all

News & Signals from Cabaletta Bio

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCabaletta Bio partnered with Cellares Corporation on Apr 1st '26.In April 2026, Cabaletta announced a 10-year commercial supply agreement with Cellares, an integrated development and manufacturing organization, building on an initial partnership established in November 2023 and expanded in August 2024.

NewsCabaletta Bio attended event ASGCT 2026 Annual Meeting on May 11th '26.PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) - Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed specifically for patients with autoimmune diseases, today announced multiple upcoming presentations including manufacturing, translational and clinical data on rese-cel (resecabtagene autoleucel) at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, being held from May 11-15, 2026, in Boston, MA.

NewsCabaletta Bio attended event 2026 American Academy of Neurology (AAN) meeting on Apr 20th '26.On April 20, at the 2026 American Academy of Neurology (AAN) meeting, Cabaletta Bio announced positive results from the Phase I/II open-label, RESET-MG study of rese-cel (resecabtagene autoleucel) in patients with generalised myasthenia gravis (gMG) (NCT06359041).